AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25315204 — intervention group
Group type: COMPARATOR
Intervention: Very low-calorie diet (VLCD)
Number of subjects: 62
Study 23053638 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐D (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) × 4 cycles)
Number of subjects: 94
Study 23053638 — intervention group
Group type: COMPARATOR
Intervention: EC‐DCb (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 75 mg/m(2) plus carboplatin AUC 6 × 4 cycles)
Number of subjects: 94
Study 23053638 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐D
Number of subjects: 94
Study 23053638 — intervention group
Group type: COMPARATOR
Intervention: EC‐DCb
Number of subjects: 94
Study 20803858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 60
Study 20803858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18589560 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg
Number of subjects: 0
Study 18589560 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg
Number of subjects: 0
Study 16078332 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-MDP uptake at baseline
Number of subjects: 174
Study 16078332 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-MDP uptake in upper and middle tertiles
Number of subjects: 174
Study 16078332 — intervention group
Group type: EXPERIMENTAL
Intervention: Kellgren-Lawrence grade 3 OA severity and greater than median WOMAC Pain score
Number of subjects: 174
Study 11868924 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 18
Study 11868924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg
Number of subjects: 18
Study 11868924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 18
Study 11868924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 18
Study 11868924 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 18
Study 11868924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9820259 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion on acupoint BL 67 for 7 days (with additional 7 days if needed)
Number of subjects: 260
Study 9820259 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion on acupoint BL 67
Number of subjects: 260
Study 9820259 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 260
Study 7715793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 57
Study 7715793 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 57
Study 2652084 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin (100 mg/kg/day for 10 days)
Number of subjects: 44
Study 2652084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 2652084 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin
Number of subjects: 44
Study 582709 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 50 mg
Number of subjects: 129
Study 582709 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg
Number of subjects: 129
Study 582709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 129
Study 582709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 31891963 — intervention group
Group type: EXPERIMENTAL
Intervention: OrthoPilot navigation system
Number of subjects: 60
Study 31891963 — intervention group
Group type: COMPARATOR
Intervention: iASSIST navigation system
Number of subjects: 60
Study 31122158 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Recovery program
Number of subjects: 77
Study 31122158 — intervention group
Group type: COMPARATOR
Intervention: Online depression program (control)
Number of subjects: 77
Study 29218623 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 63
Study 29218623 — intervention group
Group type: COMPARATOR
Intervention: PET response after chemoradiation
Number of subjects: 63
Study 26830197 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based lifestyle intervention program with motivational interviewing
Number of subjects: 401
Study 26830197 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlisted)
Number of subjects: 401
Study 23912506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative urodynamic studies
Number of subjects: 0
Study 23912506 — intervention group
Group type: COMPARATOR
Intervention: Standardized office evaluation
Number of subjects: 0
Study 22646975 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training intervention (3 sessions and an audio disc for home practice)
Number of subjects: 56
Study 22646975 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (no treatment)
Number of subjects: 56
Study 21140635 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 57
Study 21140635 — intervention group
Group type: COMPARATOR
Intervention: Traditional tonsillectomy
Number of subjects: 57
Study 17982722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) 2 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Number of subjects: 202
Study 17982722 — intervention group
Group type: COMPARATOR
Intervention: Cefotiam (CTM) 1 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Number of subjects: 202
Study 15342674 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP inhibitors
Number of subjects: 0
Study 15342674 — intervention group
Group type: COMPARATOR
Intervention: CETP deficiency
Number of subjects: 0
Study 11229617 — intervention group
Group type: EXPERIMENTAL
Intervention: delta9-THC (5.0 to 10.0 mg)
Number of subjects: 12
Study 11229617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9526990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure (Vascular Clip‐applier System)
Number of subjects: 16
Study 9526990 — intervention group
Group type: COMPARATOR
Intervention: Standard suture (running 6‐0 monofilament)
Number of subjects: 16
Study 9526990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip closure
Number of subjects: 16
Study 9526990 — intervention group
Group type: COMPARATOR
Intervention: Standard suture
Number of subjects: 16
Study 7736528 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies against CA125
Number of subjects: 58
Study 7736528 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies against TAG72
Number of subjects: 58
Study 2758104 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaprostil (50 micrograms) and Aspirin (975 mg) coadministration
Number of subjects: 0
Study 2758104 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (975 mg) alone
Number of subjects: 0
Study 2758104 — intervention group
Group type: COMPARATOR
Intervention: Arbaprostil (50 micrograms) alone
Number of subjects: 0
Study 2758104 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylate pharmacokinetics
Number of subjects: 0
Study 8049998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy or chemoradiotherapy
Number of subjects: 0
Study 8049998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 8049998 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 8049998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 0
Study 676309 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of 1200 IU vitamin D3
Number of subjects: 21
Study 676309 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of 200,000 IU vitamin D3
Number of subjects: 21
Study 30670010 — intervention group
Group type: EXPERIMENTAL
Intervention: Amla extract (500 mg) administered twice daily for 12 weeks
Number of subjects: 98
Study 30670010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 27193080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (1.5 mcg/kg) + intravenous tramadol (2 mg/kg)
Number of subjects: 20
Study 27193080 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol (2 mg/kg)
Number of subjects: 20
Study 27465265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3876
Study 27465265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876
Study 27465265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (in patients with initial impaired fasting glucose)
Number of subjects: 3876
Study 27465265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (in patients with elevated HbA1c)
Number of subjects: 3876
Study 25311995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg every 12 hours
Number of subjects: 192
Study 25311995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 23090145 — intervention group
Group type: EXPERIMENTAL
Intervention: RNMB present (train-of-four ratio < 0.9)
Number of subjects: 150
Study 23090145 — intervention group
Group type: COMPARATOR
Intervention: RNMB absent (train-of-four ratio ≥ 0.9)
Number of subjects: 150
Study 19695596 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic studies for urge syndrome
Number of subjects: 202
Study 19695596 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic studies for dysfunctional voiding
Number of subjects: 202
Study 17878730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged and exclusive breast-feeding promotion intervention
Number of subjects: 17046
Study 17878730 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 17046
Study 15354916 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine and 1 microg/kg of clonidine
Number of subjects: 64
Study 15354916 — intervention group
Group type: COMPARATOR
Intervention: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine (control group)
Number of subjects: 64
Study 11254844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam, 0.1 microg/kg/min
Number of subjects: 31
Study 11254844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9823809 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy dissection
Number of subjects: 91
Study 9823809 — intervention group
Group type: COMPARATOR
Intervention: Scissors dissection
Number of subjects: 91
Study 8210255 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (100 mg/m2 weekly intravenous infusion, regimen A)
Number of subjects: 61
Study 8210255 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (150 mg/m2 every two weeks, regimen B)
Number of subjects: 61
Study 2816967 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-antigen-content diet (LAC diet)
Number of subjects: 24
Study 2816967 — intervention group
Group type: COMPARATOR
Intervention: Standard normocaloric diet (placebo)
Number of subjects: 24
Study 802630 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic plus methyldopa
Number of subjects: 20
Study 802630 — intervention group
Group type: COMPARATOR
Intervention: Diuretic alone
Number of subjects: 20
Study 31461306 — intervention group
Group type: EXPERIMENTAL
Intervention: MSE group (tooth bone‐borne expander)
Number of subjects: 48
Study 31461306 — intervention group
Group type: COMPARATOR
Intervention: C-expander group (tissue bone‐borne expander)
Number of subjects: 48
Study 29065278 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg·kg‐1 body mass caffeine
Number of subjects: 10
Study 29065278 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg·kg‐1 body mass caffeine
Number of subjects: 10
Study 29065278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26694130 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 μg/kg/d Lenograstim from day 2 after each course of six chemotherapy courses)
Number of subjects: 58
Study 26694130 — intervention group
Group type: COMPARATOR
Intervention: G-CSF- (no G-CSF administration)
Number of subjects: 58
Study 24886606 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based behaviour change intervention
Number of subjects: 44
Study 24886606 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 21773849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Medicine Physician Worklife Survey
Number of subjects: 816
Study 20089755 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed lunches
Number of subjects: 1294
Study 18349272 — intervention group
Group type: COMPARATOR
Intervention: Flavonoid intake (fourth quartile)
Number of subjects: 27111
Study 18349272 — intervention group
Group type: COMPARATOR
Intervention: Flavonoid intake (first quartile)
Number of subjects: 27111
Study 18349272 — intervention group
Group type: COMPARATOR
Intervention: Supplemental alpha-tocopherol (50 mg/d) and/or beta-carotene (20 mg/d)
Number of subjects: 27111
Study 18349272 — intervention group
Group type: COMPARATOR
Intervention: Flavonols, flavan-3-ols, kaempferol, quercetin, catechin, and epicatechin
Number of subjects: 27111
Study 15984021 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (5 gm/day)
Number of subjects: 50
Study 15984021 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.6 gm/kg/day)
Number of subjects: 50
Study 15984021 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine and Glutamine
Number of subjects: 50
Study 15984021 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine
Number of subjects: 50
Study 15984021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 14623176 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-Guard
Number of subjects: 36
Study 14623176 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 36
Study 14623176 — intervention group
Group type: COMPARATOR
Intervention: Colchicine
Number of subjects: 36
Study 14623176 — intervention group
Group type: COMPARATOR
Intervention: Control group C
Number of subjects: 36
Study 10634837 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sodium supplementation (4 mmol/kg/day starting on day 2 after birth)
Number of subjects: 46
Study 10634837 — intervention group
Group type: COMPARATOR
Intervention: Delayed sodium supplementation (4 mmol/kg/day starting after 6% weight loss)
Number of subjects: 46
Study 10634837 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sodium supplementation
Number of subjects: 46
Study 8800584 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee drinking in normotensives (NT)
Number of subjects: 171
Study 8800584 — intervention group
Group type: COMPARATOR
Intervention: Abstaining from caffeine in untreated hypertensives (UNHT)
Number of subjects: 171
Study 8800584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea drinking in treated hypertensives (TRHT)
Number of subjects: 171
Study 8800584 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee drinking in untreated hypertensives (UNHT)
Number of subjects: 171
Study 1281650 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy with sequential methotrexate‐5‐FU with leucovorin rescue (MFL) for 6 months
Number of subjects: 183
Study 1281650 — intervention group
Group type: COMPARATOR
Intervention: Primary expectancy with chemotherapy only after the appearance of symptoms
Number of subjects: 183
Study 3977555 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mL/kg of ethanol
Number of subjects: 34
Study 3977555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mL/kg of ethanol
Number of subjects: 34
Study 3977555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31027883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (1,600 mg thrice daily) for 3 months
Number of subjects: 53
Study 31027883 — intervention group
Group type: COMPARATOR
Intervention: No sevelamer for 3 months
Number of subjects: 53
Study 31027883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer treatment
Number of subjects: 53
Study 30075908 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Number of subjects: 124
Study 30075908 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus nab-paclitaxel (GnP)
Number of subjects: 124
Study 26947315 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality treadmill training (VRTT)
Number of subjects: 18
Study 26947315 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 18
Study 24671450 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 (pooled doses)
Number of subjects: 2753
Study 24671450 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 (modified ISTH scale)
Number of subjects: 2753
Study 24671450 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-442 (various doses)
Number of subjects: 2753
Study 24671450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2753
Study 22348233 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg)
Number of subjects: 19
Study 22348233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 21809603 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable lidocaine 2% solution (1.5 ml)
Number of subjects: 61
Study 21809603 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine 2% gel (1.5 ml)
Number of subjects: 61
Study 18413426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU oral vitamin D2 daily
Number of subjects: 40
Study 18413426 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D2 weekly
Number of subjects: 40
Study 18413426 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D3 daily
Number of subjects: 40
Study 15710045 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Hsp60
Number of subjects: 95
Study 15710045 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Hsp70
Number of subjects: 95
Study 15710045 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Hsp60 and Anti-Hsp70 levels
Number of subjects: 95
Study 15710045 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of asthma
Number of subjects: 95
Study 15710045 — intervention group
Group type: EXPERIMENTAL
Intervention: Total immunoglobulin E and interleukin-4 levels
Number of subjects: 95
Study 11831538 — intervention group
Group type: EXPERIMENTAL
Intervention: ERA-923 (10-200 mg)
Number of subjects: 0
Study 11831538 — intervention group
Group type: EXPERIMENTAL
Intervention: ERA-923
Number of subjects: 0
Study 10709536 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal bite plate
Number of subjects: 9
Study 10709536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 9
Study 7851575 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE (Gore-Tex Surgical Membrane)
Number of subjects: 27
Study 7851575 — intervention group
Group type: COMPARATOR
Intervention: Control (uncovered sites)
Number of subjects: 27
Study 1682643 — intervention group
Group type: EXPERIMENTAL
Intervention: monocomponent pertussis toxoid vaccine
Number of subjects: 73
Study 1682643 — intervention group
Group type: EXPERIMENTAL
Intervention: two-component acellular vaccine also containing filamentous haemagglutinin
Number of subjects: 73
Study 1682643 — intervention group
Group type: COMPARATOR
Intervention: 20% albumin solution (placebo)
Number of subjects: 73
Study 6756799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxipor VHC lotion
Number of subjects: 0
Study 6756799 — intervention group
Group type: COMPARATOR
Intervention: Tegrin lotion
Number of subjects: 0
Study 31146090 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture
Number of subjects: 0
Study 31146090 — intervention group
Group type: COMPARATOR
Intervention: Not gesture
Number of subjects: 0
Study 31146090 — intervention group
Group type: COMPARATOR
Intervention: Manual interference task
Number of subjects: 0
Study 29074513 — intervention group
Group type: EXPERIMENTAL
Intervention: HelpMeDoIt! app/website intervention for 12 months with social support from nominated helpers.
Number of subjects: 120
Study 29074513 — intervention group
Group type: COMPARATOR
Intervention: Leaflet on healthy lifestyle (control group).
Number of subjects: 120
Study 25673560 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV detected in ILI episodes
Number of subjects: 6266
Study 25673560 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of RSV-associated ILI
Number of subjects: 6266
Study 25673560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization due to ILI episodes
Number of subjects: 6266
Study 25673560 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of RSV-associated ILI resulting in medical attendance
Number of subjects: 6266
Study 24351402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing containing ceramide (arm A)
Number of subjects: 33
Study 24351402 — intervention group
Group type: COMPARATOR
Intervention: 10% urea cream (arm B)
Number of subjects: 33
Study 22943933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (oral dosing 25 - 150 mg)
Number of subjects: 103
Study 22943933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (i.v. dosing 7.5 - 50 mg)
Number of subjects: 103
Study 22943933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (oral dosing)
Number of subjects: 103
Study 22943933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (i.v. dosing)
Number of subjects: 103
Study 22943933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (oral and i.v. dosing)
Number of subjects: 103
Study 19446846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nutrient diet
Number of subjects: 95
Study 19446846 — intervention group
Group type: COMPARATOR
Intervention: Standard-nutrient diet
Number of subjects: 95
Study 17476705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 4-16 mg per day for 12 weeks
Number of subjects: 54
Study 15148924 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 72
Study 15148924 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin, terazosin and microwave
Number of subjects: 72
Study 15148924 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin, Chinese traditional medicine and microwave
Number of subjects: 72